Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRONKOMETER vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Treatment of bronchial asthma,Reversible bronchospasm associated with bronchitis and emphysema
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Isoetharine mesylate 0.5% solution: 2-4 inhalations every 4 hours as needed via hand-held nebulizer or IPPB.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Terminal elimination half-life: 2-3 hours; clinically, bronchodilation persists but dosing interval is 3-4 hours due to rapid onset and offset.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Renal: 10-15% unchanged; 70-80% as sulfate conjugates; biliary/fecal: <5%.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
50-60% bound primarily to albumin.
55–65% bound to plasma proteins, primarily albumin.
Vd: 1-2 L/kg; indicates extensive distribution into tissues including lungs.
0.4–0.6 L/kg, indicating distribution into total body water.
Aerosol: 10-20% lung deposition; remainder swallowed with negligible oral bioavailability due to first-pass metabolism.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
No specific dose adjustment required based on GFR; clinical monitoring advised in severe renal impairment due to potential for drug accumulation.
No dose adjustment required for renal impairment.
No formal Child-Pugh based modifications established; caution in severe hepatic impairment due to possible altered metabolism.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Children 6-12 years: 1-2 inhalations every 4 hours as needed; <6 years: not recommended due to limited data.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Initiate at lower end of dosing range (1-2 inhalations every 4 hours as needed) due to increased sensitivity and concomitant comorbidities; monitor for adverse cardiovascular effects.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
No FDA black box warning.
No FDA black box warning exists for this drug.
Paradoxical bronchospasm may occur,Cardiovascular effects including increased heart rate and blood pressure,Hypokalemia may occur,Use with caution in patients with cardiovascular disorders, hyperthyroidism, diabetes, or seizure disorders,Excessive use may lead to tolerance
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to isoetharine or any component,Pre-existing cardiac arrhythmias associated with tachycardia
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may increase cardiac stimulation. No specific food restrictions, but a balanced diet is recommended. Avoid alcohol as it may worsen side effects.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
Insufficient human data; animal studies show no teratogenic effects at clinically relevant doses. Risk cannot be excluded; use only if clearly needed.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Unknown whether isoproterenol or its metabolites are excreted in human milk. Caution advised; weigh risks vs benefits. M/P ratio not available.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
No specific dose adjustments recommended; pharmacokinetic changes in pregnancy may alter response, requiring titration to effect.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
Bronkometer contains isoetharine, a beta-2 selective agonist, but less selective than albuterol. It is rarely used now due to higher cardiac side effect risk. Monitor for paradoxical bronchospasm; discontinue if occurs. Use with caution in patients with hyperthyroidism, diabetes, or hypertension.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Shake the inhaler well before each use.,Prime the inhaler by spraying 4 test sprays into the air away from face if new or not used for 3 days.,Exhale fully, then place mouthpiece in mouth and inhale slowly while pressing down on canister.,Hold breath for 10 seconds, then exhale slowly.,Wait at least 1 minute between puffs.,Rinse mouth with water after use to prevent mouth irritation.,Seek emergency care if you experience worsening shortness of breath, chest pain, or irregular heartbeat.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRONKOMETER vs AEROLATE SR, answered by our medical review team.
BRONKOMETER is a Bronchodilator that works by Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRONKOMETER and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRONKOMETER is: Isoetharine mesylate 0.5% solution: 2-4 inhalations every 4 hours as needed via hand-held nebulizer or IPPB.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRONKOMETER and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRONKOMETER is classified as Category C. Insufficient human data; animal studies show no teratogenic effects at clinically relevant doses. Risk cannot be excluded; use only if clearly needed.. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.